Exelixis (EXEL)
(Delayed Data from NSDQ)
$23.53 USD
-0.18 (-0.76%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $23.54 +0.01 (0.04%) 6:40 PM ET
2-Buy of 5 2
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
EXEL 23.53 -0.18(-0.76%)
Will EXEL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXEL
EXEL vs. REGN: Which Stock Is the Better Value Option?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
EXEL or REGN: Which Is the Better Value Stock Right Now?
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Other News for EXEL
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis slips as Barclays downgrades on lack of catalysts
Exelixis just downgraded at Barclays, here's why
Barclays downgrades Exelixis (EXEL) to a Hold
What Analysts Are Saying About Exelixis Stock